MPB-2043 not checked

MegaPro Biomedical Co. Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.”In the company’s words, NCT06540443 on ClinicalTrials.gov
Tested for
Head and Neck Squamous Cell Carcinoma, Lymph Node Metastasis
Main trialPhase 1
“This study evaluates the safety and effectiveness of MPB-2043, a superparamagnetic iron oxide (SPIO) contrast agent, for enhancing MRI in detecting metastatic lymph nodes in head and neck cancer. The study compares four doses of MPB-2043 (0.5 mg/kg, 1 mg/kg, 2 mg/kg, and 3 mg/kg) and assesses the optimal timing for post-dose imaging using T1/T2/T2\*-weighted sequences to improve the accuracy of nodal staging.”In the company’s words, NCT06540443 on ClinicalTrials.gov

Other drugs for Head and Neck Squamous Cell Carcinoma

All 198 drugs for Head and Neck Squamous Cell Carcinoma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Jun 2026 Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow MPB-2043

Following is part of Solo: you see every change to MPB-2043 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in